Drug development
Developing medicines is a long and risky journey. Many promising compounds fail along the way due to lack of efficacy, safety issues, complex regulatory requirements, or simply insufficient funding.
At RISE, all expertise is gathered under one roof, making it possible to advance projects across different types of APIs, whether it is biologics or small-molecule drugs. Within biologics, including vaccines, antibodies, mRNA, and cell and gene therapies, we focus on formulation, stability, and immunological properties to ensure the API performs as intended. For small-molecule drugs, we ensure robust synthetic routes, high purity, and reproducibility, including safe handling of highly potent APIs (HPAPIs) when required.
Sustainability and regulatory compliance are integrated throughout the process, and we also support companies in navigating opportunities for public funding.
End-to-end CDMO services for small molecules
Robust synthesis and stable processes are required for small-molecule drugs. RISE provides comprehensive support throughout the entire process, from drug substance development to clinical materials, offering expertise, analytical services and regulatory g
End-to-end CDMO services for biologics
Biological medicines such as vaccines and antibodies require precision and stability. RISE offers comprehensive support from substance characterization to clinical materials—experts, laboratories, and methods in an integrated workflow.
